H.C. Wainwright analyst Raghuram Selvaraju downgraded Assertio (ASRT) to Neutral from Buy with a price target of $18, down from $35, after the company agreed to be acquired by Garda Therapeutics for $18 per share in cash.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASRT: